公开(公告)号：US12194032B2

公开(公告)日：2025-01-14

申请号：US17658494

申请日：2022-04-08

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K31/137 ,  A61K31/28 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/7034 ,  A61K35/545 ,  A61K39/395 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US11773091B2

公开(公告)日：2023-10-03

申请号：US17735283

申请日：2022-05-03

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Rajinder Singh ,  Hiroko Tanaka ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D471/04 ,  A61P37/02 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61P37/02 ,  C07D519/00

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I)




or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US11485708B2

公开(公告)日：2022-11-01

申请号：US16905979

申请日：2020-06-19

Applicant: CHEMOCENTRYX, INC.

Inventor： Viengkham Malathong ,  Pingchen Fan ,  Christopher Lange ,  Venkat Reddy Mali ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: C07D217/04 ,  A61K45/06 ,  C07D401/12 ,  A61K31/4725 ,  C07C217/58 ,  A61K31/137 ,  C07D211/58 ,  A61K31/4468 ,  A61K31/4545 ,  C07C229/16 ,  A61K31/197 ,  C07D207/06 ,  A61K31/40 ,  C07D319/18 ,  A61K31/357 ,  C07D213/64 ,  A61K31/4402 ,  C07D215/227 ,  A61K31/4704 ,  C07C309/14 ,  A61K31/185 ,  A61K31/472

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R5, R6, R7, R8 and the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20220296601A1

公开(公告)日：2022-09-22

申请号：US17805280

申请日：2022-06-03

Applicant: CHEMOCENTRYX, INC.

Inventor： Zhenhua MIAO ,  Thomas J. Schall ,  Rajinder Singh

IPC: A61K31/519 ,  A61K31/41 ,  A61P13/12 ,  A61K31/437 ,  A61K31/422

Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.

公开(公告)号：US11059834B2

公开(公告)日：2021-07-13

申请号：US16504536

申请日：2019-07-08

Applicant: CHEMOCENTRYX, INC.

Inventor： Viengkham Malathong ,  Jeffrey McMahon ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Penglie Zhang

IPC: C07D498/08 ,  A61P37/02 ,  A61P31/12 ,  A61P31/04 ,  A61P31/10 ,  A61P35/00

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US10988464B2

公开(公告)日：2021-04-27

申请号：US16414272

申请日：2019-05-16

Applicant: CHEMOCENTRYX, INC.

Inventor： Xi Chen ,  Dean R. Dragoli ,  Junfa Fan ,  Jaroslaw Kalisiak ,  Antoni Krasinski ,  Manmohan Reddy Leleti ,  Venkat Mali ,  Jeffrey McMahon ,  Rajinder Singh ,  Hiroko Tanaka ,  Ju Yang ,  Chao Yu ,  Penglie Zhang

IPC: C07D405/14 ,  A61P35/00 ,  A61K31/341 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/506 ,  A61K45/06 ,  C07D209/46 ,  C07D307/52 ,  C07D405/12

Abstract: Compounds are provided as chemokine inhibitors having the structure:

公开(公告)号：US10759807B2

公开(公告)日：2020-09-01

申请号：US16226898

申请日：2018-12-20

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Rajinder Singh ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4162 ,  A61P35/00 ,  A61P19/02 ,  A61P11/00 ,  A61P25/28 ,  A61P37/06 ,  A61P7/00 ,  A61K9/10 ,  A61K9/08

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US12139475B2

公开(公告)日：2024-11-12

申请号：US17816614

申请日：2022-08-01

Applicant: CHEMOCENTRYX, INC.

Inventor： Xi Chen ,  Dean R. Dragoli ,  Pingchen Fan ,  Manmohan Reddy Leleti ,  Rebecca M. Lui ,  Viengkham Malathong ,  Jay P. Powers ,  Rajinder Singh ,  Hiroko Tanaka ,  Ju Yang ,  Chao Yu ,  Penglie Zhang

IPC: C07D405/04 ,  A61P1/00 ,  A61P11/00 ,  A61P17/00 ,  A61P19/00 ,  A61P35/00 ,  C07D209/34 ,  C07D401/04 ,  C07D405/14

Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

公开(公告)号：US11872217B2

公开(公告)日：2024-01-16

申请号：US16924385

申请日：2020-07-09

Applicant: CHEMOCENTRYX, INC.

Inventor： Viengkham Malathong ,  Venkat Reddy Mali ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/444 ,  C07D401/12 ,  C07C229/36 ,  C07C219/28 ,  C07C309/24 ,  C07D207/267 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/197 ,  A61K31/137 ,  A61K31/4015 ,  A61K31/4188 ,  C07D487/10

CPC classification number: A61K31/444 ,  A61K31/137 ,  A61K31/197 ,  A61K31/397 ,  A61K31/4015 ,  A61K31/4188 ,  A61K31/4545 ,  C07C219/28 ,  C07C229/36 ,  C07C309/24 ,  C07D207/267 ,  C07D401/12 ,  C07D487/10

Abstract: Compounds represented by Formula (I) or (II):




are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a′, R2b′, R2c′, R3′, R4′, R5′, R6a′, R6b′, Y, Y′, and the subscripts m and n are as defined herein.

公开(公告)号：US11807609B2

公开(公告)日：2023-11-07

申请号：US17066986

申请日：2020-10-09

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Rebecca M. Lui ,  Venkat Reddy Mali ,  Rajinder Singh ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D211/60 ,  A61K45/06 ,  A61K31/451

CPC classification number: C07D211/60 ,  A61K31/451 ,  A61K45/06 ,  C07B2200/05

Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I):




including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.